Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Guided Therapeutics (GTHP) Notes Payables (2016 - 2025)

Historic Notes Payables for Guided Therapeutics (GTHP) over the last 15 years, with Q3 2025 value amounting to $411000.0.

  • Guided Therapeutics' Notes Payables rose 8026.32% to $411000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $411000.0, marking a year-over-year increase of 8026.32%. This contributed to the annual value of $139000.0 for FY2024, which is 13559.32% up from last year.
  • As of Q3 2025, Guided Therapeutics' Notes Payables stood at $411000.0, which was up 8026.32% from $421000.0 recorded in Q2 2025.
  • Guided Therapeutics' 5-year Notes Payables high stood at $745000.0 for Q1 2022, and its period low was $23000.0 during Q1 2023.
  • For the 5-year period, Guided Therapeutics' Notes Payables averaged around $211841.9, with its median value being $125500.0 (2024).
  • Per our database at Business Quant, Guided Therapeutics' Notes Payables soared by 59759.04% in 2022 and then crashed by 9691.28% in 2023.
  • Over the past 5 years, Guided Therapeutics' Notes Payables (Quarter) stood at $161000.0 in 2021, then tumbled by 64.6% to $57000.0 in 2022, then increased by 3.51% to $59000.0 in 2023, then surged by 135.59% to $139000.0 in 2024, then surged by 195.68% to $411000.0 in 2025.
  • Its Notes Payables was $411000.0 in Q3 2025, compared to $421000.0 in Q2 2025 and $48000.0 in Q1 2025.